Novo Nordisk's FDA-Approved GLP-1s Now on Hims & Hers
In a major development for weight management and metabolic health, Hims & Hers Health, Inc. (NYSE: HIMS) announced on March 26, 2026, that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are now available to eligible customers. This includes the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 Through a new collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access these medications at more affordable prices, with more doses and delivery methods. This positions Hims & Hers as the largest global consumer health platform for affordable access to approved medications.
What Are GLP-1 Medications and Why Do They Matter?
GLP-1 medications, or glucagon-like peptide-1 receptor agonists, mimic the GLP-1 hormone naturally produced in the gut. This hormone plays a key role in regulating blood sugar, slowing gastric emptying, and signaling fullness to the brain, which helps reduce appetite and promote weight loss. Novo Nordisk's FDA-approved GLP-1s, such as those now available via Hims & Hers, target these mechanisms to support sustainable weight management, especially for individuals with obesity or related conditions.
The significance of this announcement lies in expanded accessibility. Previously, obtaining GLP-1s often involved navigating insurance hurdles, specialist visits, or high out-of-pocket costs. Hims & Hers' integration changes that by offering a streamlined telehealth platform where eligible patients can consult providers and receive prescriptions efficiently.
How GLP-1s Like Wegovy Work
The Wegovy® pill stands out as the only FDA-approved GLP-1 weight loss pill, providing a convenient oral option alongside injectable forms. These medications activate GLP-1 receptors in the pancreas, brain, and stomach, leading to improved insulin secretion, reduced glucagon release, and prolonged satiety. For patients, this translates to meaningful weight reduction—often 15% or more of body weight in clinical use—while also benefiting cardiovascular health markers.
The Hims & Hers and Novo Nordisk Collaboration Explained
This partnership directly addresses common barriers to GLP-1 therapy. Hims & Hers customers can now access a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications, including varied doses and delivery methods like pills and injections. Key benefits include:
- Affordable pricing: Lower costs compared to traditional pharmacies or direct manufacturer channels.
- More options: Expanded dose strengths to match individual needs, from initiation to maintenance.
- Simplified process: Online consultations, prescriptions, and home delivery for eligible users.
SAN FRANCISCO--(BUSINESS WIRE)--Mar 26, 2026—Hims & Hers Health, Inc. (NYSE: HIMS) today announced that these medications are available, solidifying their role as the premier platform for consumer access.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Eligibility and Getting Started
Not everyone qualifies for GLP-1s, as they are FDA-approved for specific indications like chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Eligible Hims & Hers customers typically start with a virtual consultation to assess suitability. Factors include medical history, current weight, and comorbidities. Always discuss with a healthcare provider to confirm if Novo Nordisk's GLP-1s align with your goals.
Practical Guidance for Patients Considering GLP-1s via Hims & Hers
For those exploring this option, here's what to know:
- Consultation first: Use Hims & Hers' platform for a quick eligibility check.
- Dosing progression: Start low to minimize side effects, titrating up as tolerated—now with more flexible options through this collaboration.
- Lifestyle integration: Pair GLP-1s with diet, exercise, and monitoring for best results. Apps like Shotlee can help track symptoms, side effects, or medication schedules during your journey.
Compared to alternatives like compounded semaglutide or other platforms, Hims & Hers emphasizes FDA-approved products from Novo Nordisk, ensuring quality and safety standards.
Safety and Common Side Effects
GLP-1 medications are generally well-tolerated but can cause gastrointestinal issues like nausea, vomiting, diarrhea, or constipation, especially during dose escalation. Rare risks include pancreatitis or gallbladder issues. Hims & Hers provides guidance on management, and monitoring tools can aid adherence. This collaboration's affordable access doesn't compromise on provider support or follow-up care.
What This Means for Metabolic Health and Beyond
By making Novo Nordisk's GLP-1s more accessible, Hims & Hers empowers patients to tackle obesity—a driver of diabetes, heart disease, and more. The inclusion of the Wegovy® pill offers a needle-free entry point, appealing to those hesitant about injections. As the largest global consumer health platform in this space, Hims & Hers sets a new standard for equitable access.
Key Takeaways
- Hims & Hers now offers Novo Nordisk's FDA-approved GLP-1s, including the Wegovy® pill.
- Affordable prices, more doses, and delivery methods via collaboration.
- Simplifies access for eligible customers on the largest platform for these meds.
- Consult a provider to determine eligibility and start safely.
Conclusion: A Step Forward in Accessible Weight Management
This announcement from Hims & Hers marks a pivotal moment for GLP-1 therapy. Patients seeking FDA-approved options like the Wegovy® pill can now pursue them conveniently and cost-effectively. Discuss with your doctor, explore eligibility on Hims & Hers, and take actionable steps toward better metabolic health today.
